Improvement in motor symptoms, physical fatigue, and self-rated change perception in functional motor disorders: a prospective cohort study of a 12-week telemedicine program.

Anxiety Depression Gait disorders Motor symptoms Physical fatigue Quality of life Telemedicine

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 12 05 2022
accepted: 13 06 2022
revised: 13 06 2022
pubmed: 10 7 2022
medline: 14 10 2022
entrez: 9 7 2022
Statut: ppublish

Résumé

Functional motor disorders (FMDs) are highly disabling conditions associated with long-term disability, poor quality of life, and economic burden on health and social care. While multidisciplinary 5-days rehabilitation programs have been shown to reduce motor and non-motor symptoms, long-term management and monitoring in FMDs remain an unmet need. To compare a 12-weeks telemedicine program against a 12-weeks self-management program after a 5-days rehabilitation program for improving motor, non-motor symptoms, quality of life, and perception of change in patients with FMDs. The study population was 64 consecutive patients with a definite diagnosis of FMDs who underwent a 5-days in-person rehabilitation program followed by either a self-management (the first 32 patients) or a telemedicine program (the latter 32 patients). Validated measures of motor and non-motor symptoms such as fatigue and pain, quality of life, perception of change, gait, and postural control were recorded before (T0), after completion of rehabilitation (T1), and then again at 3 months (T2). Improvement at 3-month follow-up assessment of motor symptoms (p < 0.001), physical fatigue (p = 0.028), and self-rated change perception (p = 0.043) was greater in the telemedicine group. No different between-groups effect was found on other dimensions of fatigue, pain, physical and mental health, and gait and postural control. Long-term management and expert monitoring of patients with FMDs via telemedicine may enhance long-term outcomes in motor symptoms and physical fatigue, with a positive long-term impact on self-rated health perception of change.

Sections du résumé

BACKGROUND BACKGROUND
Functional motor disorders (FMDs) are highly disabling conditions associated with long-term disability, poor quality of life, and economic burden on health and social care. While multidisciplinary 5-days rehabilitation programs have been shown to reduce motor and non-motor symptoms, long-term management and monitoring in FMDs remain an unmet need.
AIM OBJECTIVE
To compare a 12-weeks telemedicine program against a 12-weeks self-management program after a 5-days rehabilitation program for improving motor, non-motor symptoms, quality of life, and perception of change in patients with FMDs.
METHODS METHODS
The study population was 64 consecutive patients with a definite diagnosis of FMDs who underwent a 5-days in-person rehabilitation program followed by either a self-management (the first 32 patients) or a telemedicine program (the latter 32 patients). Validated measures of motor and non-motor symptoms such as fatigue and pain, quality of life, perception of change, gait, and postural control were recorded before (T0), after completion of rehabilitation (T1), and then again at 3 months (T2).
RESULTS RESULTS
Improvement at 3-month follow-up assessment of motor symptoms (p < 0.001), physical fatigue (p = 0.028), and self-rated change perception (p = 0.043) was greater in the telemedicine group. No different between-groups effect was found on other dimensions of fatigue, pain, physical and mental health, and gait and postural control.
CONCLUSIONS CONCLUSIONS
Long-term management and expert monitoring of patients with FMDs via telemedicine may enhance long-term outcomes in motor symptoms and physical fatigue, with a positive long-term impact on self-rated health perception of change.

Identifiants

pubmed: 35809125
doi: 10.1007/s00415-022-11230-8
pii: 10.1007/s00415-022-11230-8
pmc: PMC9552134
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

5940-5953

Informations de copyright

© 2022. The Author(s).

Références

J Neurol Neurosurg Psychiatry. 2015 Oct;86(10):1113-9
pubmed: 25433033
Epilepsia. 2020 Nov;61(11):2572-2582
pubmed: 33015831
Neurol Clin Pract. 2016 Apr;6(2):138-149
pubmed: 27104066
Brain. 2017 Aug 1;140(8):2240-2245
pubmed: 28899013
Parkinsonism Relat Disord. 2020 Jul;76:108-111
pubmed: 31078400
Biomed Res Int. 2017;2017:7962826
pubmed: 29333454
JAMA Neurol. 2018 Sep 1;75(9):1132-1141
pubmed: 29868890
J Neurol Neurosurg Psychiatry. 2021 Mar 15;:
pubmed: 33722822
Front Hum Neurosci. 2017 Jun 06;11:291
pubmed: 28634447
NeuroRehabilitation. 2022;50(2):245-254
pubmed: 35213333
Lancet Neurol. 2012 Mar;11(3):250-60
pubmed: 22341033
J Neurol. 2018 Aug;265(8):1803-1809
pubmed: 29860667
J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):638-649
pubmed: 32111637
Neuropsychiatr Dis Treat. 2020 Sep 18;16:2119-2134
pubmed: 32982250
Mov Disord Clin Pract. 2020 Sep 22;7(8):920-929
pubmed: 33163563
CNS Spectr. 2020 Sep 04;:1-7
pubmed: 32883381
Med Care. 1996 Mar;34(3):220-33
pubmed: 8628042
Curr Treat Options Neurol. 2014 Apr;16(4):286
pubmed: 24566832
J Telemed Telecare. 2018 Sep;24(8):511-526
pubmed: 28696152
Handb Clin Neurol. 2017;139:47-60
pubmed: 27719864
Disabil Rehabil. 2020 Jul;42(14):2043-2048
pubmed: 30669889
Clin Park Relat Disord. 2022 Mar 01;6:100139
pubmed: 35252835
Brain. 2012 Jan;135(Pt 1):117-23
pubmed: 22075068
J Psychosom Res. 2019 Jan;116:10-16
pubmed: 30654984
Parkinsonism Relat Disord. 2012 Mar;18(3):247-51
pubmed: 22113131
Can J Neurol Sci. 2021 Mar;48(2):204-217
pubmed: 32690119
Front Neurol. 2021 Dec 08;12:786126
pubmed: 34956066
J Neurol. 2021 Dec;268(12):4737-4743
pubmed: 33961091
J Neurol. 2015 Mar;262(3):674-81
pubmed: 25557282
Parkinsonism Relat Disord. 2015 May;21(5):529-32
pubmed: 25772324
NeuroRehabilitation. 2021;48(3):305-314
pubmed: 33780378
Curr Opin Neurol. 2013 Aug;26(4):442-7
pubmed: 23823467
Handb Clin Neurol. 2017;139:131-137
pubmed: 27719834
Curr Opin Neurol. 2009 Aug;22(4):430-6
pubmed: 19542886
Lancet Neurol. 2017 Jul;16(7):541-551
pubmed: 28566190
J Psychosom Res. 2018 Dec;115:32-37
pubmed: 30470314
J Psychosom Res. 1996 Dec;41(6):551-9
pubmed: 9032718
Neurol Clin Pract. 2017 Apr;7(2):141-147
pubmed: 29185540
Eur J Neurol. 2021 May;28(5):1752-1758
pubmed: 33300269
Pain. 1996 Apr;65(1):87-92
pubmed: 8826494
J Psychosom Res. 1995 Apr;39(3):315-25
pubmed: 7636775
Br J Sports Med. 2021 Feb;55(3):155-162
pubmed: 33060156
Eur J Neurol. 2021 Dec;28(12):3921-3924
pubmed: 34478601
Parkinsonism Relat Disord. 2021 Dec;93:40-42
pubmed: 34784525
J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):484-490
pubmed: 27694498
Physiotherapy. 2017 Jun;103(2):180-185
pubmed: 27913064
Neurol Clin Pract. 2021 Oct;11(5):e686-e690
pubmed: 34840884
J Neurol Neurosurg Psychiatry. 2011 Jul;82(7):810-3
pubmed: 21257981
J Neuropsychiatry Clin Neurosci. 2016 Summer;28(3):168-90
pubmed: 26900733
J Neurol. 2020 Jul;267(7):2164-2172
pubmed: 32193596
NeuroRehabilitation. 2022;50(2):231-243
pubmed: 35213332
Brain. 2012 Nov;135(Pt 11):3495-512
pubmed: 22641838
JMIR Rehabil Assist Technol. 2017 Jul 21;4(2):e7
pubmed: 28733271
Curr Opin Neurol. 2017 Aug;30(4):427-434
pubmed: 28590986

Auteurs

Marialuisa Gandolfi (M)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy. marialuisa.gandolfi@univr.it.
Neuromotor and Cognitive Rehabilitation Research Centre (CRRNC), University of Verona, Verona, Italy. marialuisa.gandolfi@univr.it.

Angela Sandri (A)

Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy.

Christian Geroin (C)

Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy.

Federica Bombieri (F)

Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy.

Marianna Riello (M)

Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy.

Zoe Menaspà (Z)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Neuromotor and Cognitive Rehabilitation Research Centre (CRRNC), University of Verona, Verona, Italy.
Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy.

Chiara Bonetto (C)

Department of Neurosciences, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.

Nicola Smania (N)

Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Neuromotor and Cognitive Rehabilitation Research Centre (CRRNC), University of Verona, Verona, Italy.

Michele Tinazzi (M)

Department of Neurosciences, Biomedicine and Movement Sciences, Neurology Unit, University of Verona, Verona, Italy. michele.tinazzi@univr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH